Download Files:
NADPH oxidase-IN-1
$150 – $1,200
Products Details
Product Description
– NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy[1].
Web ID
– HY-152026
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Molecular Formula
– C20H27N3O2S
References
– [1]Shim S, et al. Discovery of a NADPH oxidase inhibitor,(E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl) amino) benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson’s disease[J]. European Journal of Medicinal Chemistry, 2022, 244: 114854.
CAS Number
– 2762405-17-2
Molecular Weight
– 373.51
Compound Purity
– 99.60
SMILES
– CN(C1=CC=C(C=C1)/C=C2C(N(C(N2C)=S)C3CCCCC3)=O)CCO
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– NADPH Oxidase
Isoform
– NOX2;NOX4
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
